Analysts Set Relmada Therapeutics, Inc. (NASDAQ:RLMD) Price Target at $4.25
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) has earned an average recommendation of “Hold” from the five research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has assigned a buy recommendation to the […]
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) has earned an average recommendation of “Hold” from the five research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has assigned a buy recommendation to the […]
